New transplant option for diabetics: islets bypass drug approval, gain regulatory clarity
H.R. 8018 — ISLET Act · Filed by Ralph Norman (R-SC) · 6 cosponsors · Introduced Mar 19, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill adds human cadaveric islets (insulin-producing cells from deceased donors' pancreases) to the list of organs that can be transplanted under federal law, and explicitly excludes them from regulation as drugs, biological products, or tissue products. It directs the HHS Secretary to update FDA and transplant regulations within one year to implement this change.
Why we flagged it
The bill's core function is to add a specific cell therapy (human cadaveric islets) to the federal transplant framework and carve it out from drug/biological product regulation. This is a narrow regulatory classification amendment, not a broad deregulation or industry giveaway.
What the text implies
- Exemption from FDA drug approval (21 U.S.C. § 201(g)) and biological product review (42 U.S.C. § 351(i)) may accelerate islet transplant availability but also means islet products will not undergo the same safety/efficacy vetting as FDA-approved drugs; oversight will rely on transplant-specific regulations (parts F, G, H of PHS Act) instead.
- Exclusion from HCT/P regulation (21 CFR 1271.3) removes islet transplants from tissue-banking standards; the bill assumes transplant regulations will fill that gap, but if HHS regulations lag, there may be a temporary oversight gap.
- The bill does not address procurement, allocation, or equity in islet distribution; access will depend on transplant center capacity and organ procurement networks, potentially creating geographic or socioeconomic disparities in availability.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Patients with type 1 diabetes and end-stage renal disease gain access to a potentially life-extending transplant option (islet transplantation can restore insulin independence). Regulatory clarity and exemption from drug approval pathways may accelerate availability. No identified cost to ordinary citizens; the bill does not restrict access, impose fees, or shift liability.
Who stands to gain
- transplant centers and hospitals performing islet transplantation
- organ procurement organizations
- islet isolation and processing facilities
Named in the bill
HHS Secretary, FDA, Public Health Service Act (Section 374(d)(2)), Federal Food, Drug, and Cosmetic Act (Section 201(g)), Title 21 CFR 1271.3, transplant programs
Where it stands
6 cosponsors: 6 Republicans.
- Mar 19, 2026 — Introduced · Congress.gov: “Introduced in House”
- Mar 19, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
2 lobbying clients named this bill on 5 disclosure filings across 3 quarters, Mar 2026 to Sep 2026. Those filings disclosed $770,000 in lobbying spend. A filing names 7 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 36% of bills with at least one filing.
Ralph Norman, the sponsor, reported $120,020 in PAC receipts in the 2026 cycle.
- Breakthrough T1d (formerly Known As Jdrf Intl.) — $650,000 on 3 filings
- Breakthrough T1d (fka Juvenile Diabetes Research Foundation International) — $120,000 on 2 filings
Lobbying Disclosure Act filings through Oct 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (1,453 characters) on Nov 13, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Mar 2026 to Sep 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Oct 20, 2026 · page rendered 2026-11-22.
- H.R. 8018 on Congress.gov
- Actions and status history
- Cosponsors (6)
- Bill text the analysis read
- Breakthrough T1d (formerly Known As Jdrf Intl.) — LDA filing, 2026 Q1
- Breakthrough T1d (fka Juvenile Diabetes Research Foundation International) — LDA filing, 2026 Q3
- Ralph Norman — FEC candidate receipts, 2026 cycle
“New transplant option for diabetics: islets bypass drug approval, gain regulatory clarity” QuorumCivic. https://share.quorumcivic.app/bill/119/hr8018 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.